Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2005 - 2007
  • Chief Medical Resident -Duke Hospital, Medicine, Duke University 2004 - 2005
  • Fellow in Hematology-Oncology, Medicine, Duke University 2003 - 2004
  • Medical Resident, Medicine, Duke University 2000 - 2003
  • M.D., State University of New York - Buffalo 2000
• 

  Previous Appointments & Affiliations

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2020
  • Assistant Professor of Medici, Medicine, Medical Oncology, Medicine 2013
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2008 - 2012
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2008
  • Associate in the Department of Medicine, Medicine, Gastroenterology, Medicine 2004 - 2005
• Recognition
• 

  In the News

  • NOV 21, 2017

    Five Recognized With Inaugural Palliative Care Award
• Expertise
• 

  Subject Headings

  • Adenocarcinoma
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Ampulla of Vater
  • Anastomotic Leak
  • Angiogenesis Inhibitors
  • Aniline Compounds
  • Anoxia
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Anus Neoplasms
  • Anxiety
  • Bevacizumab
  • Carcinoma, Squamous Cell
  • Chemoradiotherapy
  • Chemoradiotherapy, Adjuvant
  • Colorectal Neoplasms
  • Combined Modality Therapy
  • Common Bile Duct Neoplasms
  • Depression
  • Esophagectomy
  • Female
  • Follow-Up Studies
  • Gastrointestinal Neoplasms
  • Humans
  • Hydroxamic Acids
  • Hypocalcemia
  • Hypokalemia
  • Immunosuppressive Agents
  • Injections, Intravenous
  • Kaplan-Meier Estimate
  • Language
  • Leukocytes, Mononuclear
  • Liver Neoplasms
  • Lymph Nodes
  • Lymphatic Irradiation
  • Male
  • Middle Aged
  • Models, Statistical
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local
  • Organoplatinum Compounds
  • Oxaliplatin
  • Pain Measurement
  • Palliative Care
  • Pancreatic Neoplasms
  • Patient Satisfaction
  • Photons
  • Platinum Compounds
  • Protein Kinase Inhibitors
  • Psychometrics
  • Pyrimidines
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Regression Analysis
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Factors
  • Sirolimus
  • Socioeconomic Factors
  • Sulfonamides
  • Survival Rate
  • Thiazoles
  • Tumor Markers, Biological
  • Young Adult
• Research
• 

  Selected Grants

  • DEK-DKK1-P205 awarded by Leap Therapeutics, Inc. 2020 - 2025
  • An mHealth Symptom Management Intervention for Colorectal Cancer Patients awarded by American Cancer Society, Inc. 2021 - 2024
  • A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo asFirst-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Juncti awarded by Merck Sharp & Dohme 2018 - 2023
  • Key-LARGO: A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients with Gastro-esophageal Cancer," awarded by Merck Sharp & Dohme 2017 - 2022
  • A Randomized multicenter double blind Phase III study of Nivolumab or placebo in subjects with resected esophageal junction cancer. awarded by Bristol-Myers Squibb Company 2016 - 2022
  • A Phase 1b/2 open label dose escalation study of Margetuximab incombination with Pembrolizumab in patients with relapsed refrectory advanced HER2 + Gastroesophageal junction or gastric cancer. awarded by MacroGenics, Inc. 2016 - 2021
  • Multiple Co-occurring Symptoms in Patients with Gastrointestinal Cancers awarded by American Cancer Society, Inc. 2020 - 2021
  • A Multicenter randomized open label study in patients with esophageal cancer refractory or intorlerant to combination therapy with fluoropyrimidine awarded by Bristol-Myers Squibb Company 2016 - 2021
  • LYC-55716-1001 awarded by Lycera Corporation 2017 - 2020
  • A Phase 2 study of ADXS11-001 i subjects with persistent/recurrent loco-regional or metastatic squamous cell carcinoma of the anorectal canal. awarded by Advaxis Inc 2015 - 2019
• 

  External Relationships

  • Adaptimmune
  • AstraZeneca
  • Bristol-Myers Squibb
  • Leap Therapeutics
  • Macrogenics, Inc.
  • Merck
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Kelleher, Sarah A., Hannah M. Fisher, Joseph G. Winger, Shannon N. Miller, Grace H. Amaden, Tamara J. Somers, Luana Colloca, Hope E. Uronis, and Francis J. Keefe. “Virtual reality for improving pain and pain-related symptoms in patients with advanced stage colorectal cancer: A pilot trial to test feasibility and acceptability.” Palliat Support Care 20, no. 4 (August 2022): 471–81. https://doi.org/10.1017/S1478951521002017.
       Full Text  Link to Item
    • Madan, Ankit, Hope E. Uronis, and John H. Strickler. “A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer.” J Gastrointest Oncol 13, no. 4 (August 2022): 2007–19. https://doi.org/10.21037/jgo-22-55.
       Full Text  Link to Item
    • Kelleher, Sarah A., Hannah M. Fisher, Joseph G. Winger, Tamara J. Somers, Hope E. Uronis, Arianna N. Wright, and Francis J. Keefe. “Feasibility, engagement, and acceptability of a behavioral pain management intervention for colorectal cancer survivors with pain and psychological distress: data from a pilot randomized controlled trial.” Support Care Cancer 29, no. 9 (September 2021): 5361–69. https://doi.org/10.1007/s00520-021-06126-8.
       Full Text  Link to Item
    • Strickler, John H., Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, et al. “Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.” Oncologist 26, no. 6 (June 2021): 465-e917. https://doi.org/10.1002/onco.13678.
       Full Text  Link to Item
    • Kelly, Ronan J., Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Mendez, et al. “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.” N Engl J Med 384, no. 13 (April 1, 2021): 1191–1203. https://doi.org/10.1056/NEJMoa2032125.
       Full Text  Link to Item
    • Creasy, John M., Kyle J. Napier, Sarah A. Reed, Sabino Zani, Terence Z. Wong, Charles Y. Kim, Benjamin Wildman-Tobriner, et al. “Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases.” Ann Surg Oncol 27, no. 13 (December 2020): 5086–95. https://doi.org/10.1245/s10434-020-08972-y.
       Full Text  Link to Item
    • Sohal, Davendra P. S., Erin B. Kennedy, Pelin Cinar, Thierry Conroy, Mehmet S. Copur, Christopher H. Crane, Ignacio Garrido-Laguna, et al. “Metastatic Pancreatic Cancer: ASCO Guideline Update.” J Clin Oncol, August 5, 2020, JCO2001364. https://doi.org/10.1200/JCO.20.01364.
       Full Text  Link to Item
    • Catenacci, Daniel V. T., Yoon-Koo Kang, Haeseong Park, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, et al. “Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.” Lancet Oncol 21, no. 8 (August 2020): 1066–76. https://doi.org/10.1016/S1470-2045(20)30326-0.
       Full Text  Link to Item
    • Cinar, Pelin, Timothy Kubal, Alison Freifeld, Asmita Mishra, Lawrence Shulman, James Bachman, Rafael Fonseca, et al. “Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe.” J Natl Compr Canc Netw, April 15, 2020, 1–6. https://doi.org/10.6004/jnccn.2020.7572.
       Full Text  Link to Item
    • Eng, Cathy, Marwan Fakih, Manik Amin, Van Morris, Howard S. Hochster, Patrick M. Boland, and Hope Uronis. “A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer.” Oncotarget 11, no. 15 (April 14, 2020): 1334–43. https://doi.org/10.18632/oncotarget.27536.
       Full Text  Link to Item
    • Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.
       Full Text  Link to Item
    • Sohal, Davendra P. S., Erin B. Kennedy, Alok Khorana, Mehmet S. Copur, Christopher H. Crane, Ignacio Garrido-Laguna, Smitha Krishnamurthi, et al. “Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.” J Clin Oncol 36, no. 24 (August 20, 2018): 2545–56. https://doi.org/10.1200/JCO.2018.78.9636.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.
       Full Text  Link to Item
    • Porter, Laura S., Francis J. Keefe, Donald H. Baucom, Maren Olsen, S Yousuf Zafar, and Hope Uronis. “A randomized pilot trial of a videoconference couples communication intervention for advanced GI cancer.” Psychooncology 26, no. 7 (July 2017): 1027–35. https://doi.org/10.1002/pon.4121.
       Full Text  Link to Item
    • Spiegel, Daphna, Manisha Palta, and Hope Uronis. “Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma.” Surg Clin North Am 97, no. 2 (April 2017): 421–35. https://doi.org/10.1016/j.suc.2016.11.013.
       Full Text  Link to Item
    • Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors.” Cancer Chemother Pharmacol 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.
       Full Text  Link to Item
    • Susko, Matthew, Jason Lee, Joseph Salama, Samantha Thomas, Hope Uronis, David Hsu, John Migaly, Christopher Willett, Brian Czito, and Manisha Palta. “The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer.” Ann Surg Oncol 23, no. 11 (October 2016): 3609–15. https://doi.org/10.1245/s10434-016-5250-z.
       Full Text  Link to Item
    • Sohal, Davendra P. S., Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen M. O’Reilly, Hope E. Uronis, et al. “Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.” J Clin Oncol 34, no. 23 (August 10, 2016): 2784–96. https://doi.org/10.1200/JCO.2016.67.1412.
       Full Text  Link to Item
    • Borad, Mitesh J., Shantan G. Reddy, Nathan Bahary, Hope E. Uronis, Darren Sigal, Allen L. Cohn, William R. Schelman, et al. “Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.” J Clin Oncol 33, no. 13 (May 1, 2015): 1475–81. https://doi.org/10.1200/JCO.2014.55.7504.
       Full Text  Link to Item
    • Uronis, Hope E., Magnus P. Ekström, David C. Currow, Douglas C. McCrory, Gregory P. Samsa, and Amy P. Abernethy. “Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis.” Thorax 70, no. 5 (May 2015): 492–94. https://doi.org/10.1136/thoraxjnl-2014-205720.
       Full Text  Link to Item
    • Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, et al. “Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.” Mol Cancer Ther 14, no. 4 (April 2015): 1048–56. https://doi.org/10.1158/1535-7163.MCT-14-0923-T.
       Full Text  Link to Item
    • Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, et al. “A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.” Cancer Chemother Pharmacol 75, no. 2 (February 2015): 343–52. https://doi.org/10.1007/s00280-014-2647-x.
       Full Text  Link to Item
    • Zhong, Jim, Manisha Palta, Christopher G. Willett, Shannon J. McCall, Frances McSherry, Douglas S. Tyler, Hope E. Uronis, and Brian G. Czito. “Patterns of failure for stage I ampulla of Vater adenocarcinoma: a single institutional experience.” J Gastrointest Oncol 5, no. 6 (December 2014): 421–27. https://doi.org/10.3978/j.issn.2078-6891.2014.084.
       Full Text  Link to Item
    • Cleary, James M., Caio Max S Rocha Lima, Herbert I. Hurwitz, Alberto J. Montero, Catherine Franklin, Jianning Yang, Alison Graham, et al. “A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.” Invest New Drugs 32, no. 5 (October 2014): 937–45. https://doi.org/10.1007/s10637-014-0110-9.
       Full Text  Link to Item
    • Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.
       Full Text  Link to Item
    • Dorth, Jennifer A., John A. Pura, Manisha Palta, Christopher G. Willett, Hope E. Uronis, Thomas A. D’Amico, and Brian G. Czito. “Patterns of recurrence after trimodality therapy for esophageal cancer.” Cancer 120, no. 14 (July 15, 2014): 2099–2105. https://doi.org/10.1002/cncr.28703.
       Full Text  Link to Item
    • Strickler, John H., Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Invest New Drugs 32, no. 2 (April 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.
       Full Text  Link to Item
    • Jaffe, T. A., A. M. Neville, M. R. Bashir, H. E. Uronis, and J. M. Thacker. “Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis?” Colorectal Dis 15, no. 11 (November 2013): e654–58. https://doi.org/10.1111/codi.12372.
       Full Text  Link to Item
    • Meadows, Kellen L., Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, and Herbert I. Hurwitz. “Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.” Molecular Cancer Therapeutics 12, no. 11_Supplement (November 1, 2013): C61–C61. https://doi.org/10.1158/1535-7163.targ-13-c61.
       Full Text
    • Uronis, Hope E., Stephanie M. Cushman, Johanna C. Bendell, Gerard C. Blobe, Michael A. Morse, Andrew B. Nixon, Andrew Dellinger, et al. “A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.” Cancer Med 2, no. 3 (June 2013): 316–24. https://doi.org/10.1002/cam4.65.
       Full Text  Open Access Copy  Link to Item
    • Zhong, Jim, Manisha Palta, Christopher G. Willett, Shannon J. McCall, Anuradha Bulusu, Douglas S. Tyler, Rebekah R. White, Hope E. Uronis, Theodore N. Pappas, and Brian G. Czito. “The role of local excision in invasive adenocarcinoma of the ampulla of Vater.” J Gastrointest Oncol 4, no. 1 (March 2013): 8–13. https://doi.org/10.3978/j.issn.2078-6891.2012.055.
       Full Text  Link to Item
    • Pepek, Joseph M., Junzo P. Chino, Christopher G. Willett, Manisha Palta, Dan G. Blazer Iii, Douglas S. Tyler, Hope E. Uronis, and Brian G. Czito. “Preoperative chemoradiotherapy for locally advanced gastric cancer.” Radiat Oncol 8 (January 4, 2013): 6. https://doi.org/10.1186/1748-717X-8-6.
       Full Text  Link to Item
    • Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.
       Full Text  Link to Item
    • Uronis, Hope E., Rebecca A. Shelby, David C. Currow, Sam H. Ahmedzai, Hayden B. Bosworth, April Coan, and Amy P. Abernethy. “Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer.” J Pain Symptom Manage 44, no. 5 (November 2012): 741–49. https://doi.org/10.1016/j.jpainsymman.2011.10.027.
       Full Text  Link to Item
    • Strickler, John H., Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, et al. “Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251–58. https://doi.org/10.1007/s00280-012-1911-1.
       Full Text  Link to Item
    • Papalezova, Katia T., Douglas S. Tyler, Dan G. Blazer, Bryan M. Clary, Brian G. Czito, Herbert I. Hurwitz, Hope E. Uronis, Theodore N. Pappas, Christopher G. Willett, and Rebekah R. White. “Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?” J Surg Oncol 106, no. 1 (July 1, 2012): 111–18. https://doi.org/10.1002/jso.23044.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
       Full Text  Link to Item
    • Palta, Manisha, Pretesh Patel, Gloria Broadwater, Christopher Willett, Joseph Pepek, Douglas Tyler, S Yousuf Zafar, et al. “Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.” Ann Surg Oncol 19, no. 5 (May 2012): 1535–40. https://doi.org/10.1245/s10434-011-2117-1.
       Full Text  Link to Item
    • Rangwala, F. A., J. C. Bendell, M. Kozloff, C. Arrowood, J. Meadows, S. E. Tourt-Uhlig, J. Murphy, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” J Clin Oncol 30, no. 4_suppl (February 2012): 490.
       Link to Item
    • Ghafoori, A Paiman, John W. Nelson, Christopher G. Willett, Junzo Chino, Douglas S. Tyler, Herbert I. Hurwitz, Hope E. Uronis, Michael A. Morse, Robert W. Clough, and Brian G. Czito. “Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.” Int J Radiat Oncol Biol Phys 81, no. 3 (November 1, 2011): 654–59. https://doi.org/10.1016/j.ijrobp.2010.06.018.
       Full Text  Link to Item
    • Uronis, Hope, Douglas C. McCrory, Gregory Samsa, David Currow, and Amy Abernethy. “Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease.” Cochrane Database Syst Rev, no. 6 (June 15, 2011): CD006429. https://doi.org/10.1002/14651858.CD006429.pub2.
       Full Text  Link to Item
    • Czito, B. G., C. Willett, P. Kennedy-Newton, D. S. Tyler, H. Hurwitz, and H. E. Uronis. “A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC).” J Clin Oncol 29, no. 4_suppl (February 2011): 281.
       Link to Item
    • Palta, M., C. G. Willett, P. Patel, D. S. Tyler, H. E. Uronis, and B. G. Czito. “Carcinoma of the ampulla of Vater: Patterns of failure after resection and benefit of adjuvant radiotherapy.” J Clin Oncol 29, no. 4_suppl (February 2011): 254.
       Link to Item
    • Pepek, J. M., J. P. Chino, C. G. Willett, D. S. Tyler, H. E. Uronis, and B. G. Czito. “Single-institution experience of preoperative chemoradiotherapy for locally advanced gastric cancer.” J Clin Oncol 29, no. 4_suppl (February 2011): 99.
       Link to Item
    • Starodub, A., A. L. Cohn, C. Arrowood, S. Haley, M. Morse, H. E. Uronis, G. C. Blobe, S. D. Hsu, Y. Zafar, and H. Hurwitz. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” J Clin Oncol 29, no. 4_suppl (February 2011): 513.
       Link to Item
    • Bullock, Karen E., William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S Yousuf Zafar, et al. “A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 465–74. https://doi.org/10.1007/s00280-010-1507-6.
       Full Text  Link to Item
    • Czito, B. G., C. Willett, P. Kennedy-Newton, D. S. Tyler, H. Hurwitz, and H. E. Uronis. “A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC).” Journal of Clinical Oncology 29, no. 4_suppl (February 1, 2011): 281–281. https://doi.org/10.1200/jco.2011.29.4_suppl.281.
       Full Text
    • Palta, M., C. G. Willett, P. Patel, D. S. Tyler, H. E. Uronis, and B. G. Czito. “Carcinoma of the ampulla of Vater: Patterns of failure after resection and benefit of adjuvant radiotherapy.” Journal of Clinical Oncology 29, no. 4_suppl (February 1, 2011): 254–254. https://doi.org/10.1200/jco.2011.29.4_suppl.254.
       Full Text
    • Pepek, J. M., J. P. Chino, C. G. Willett, D. S. Tyler, H. E. Uronis, and B. G. Czito. “Single-institution experience of preoperative chemoradiotherapy for locally advanced gastric cancer.” Journal of Clinical Oncology 29, no. 4_suppl (February 1, 2011): 99–99. https://doi.org/10.1200/jco.2011.29.4_suppl.99.
       Full Text
    • Altomare, Ivy, Johanna C. Bendell, Karen E. Bullock, Hope E. Uronis, Michael A. Morse, S David Hsu, S Yousuf Zafar, et al. “A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.” Oncologist 16, no. 8 (2011): 1131–37. https://doi.org/10.1634/theoncologist.2011-0078.
       Full Text  Link to Item
    • Abernethy, Amy P., Syed Yousuf Zafar, Hope Uronis, Jane L. Wheeler, April Coan, Krista Rowe, Rebecca A. Shelby, Robin Fowler, and James E. Herndon. “Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.” J Pain Symptom Manage 40, no. 4 (October 2010): 545–58. https://doi.org/10.1016/j.jpainsymman.2010.01.017.
       Full Text  Link to Item
    • Abernethy, Amy P., Hope E. Uronis, Jane L. Wheeler, and David C. Currow. “Management of dyspnea in patients with chronic obstructive pulmonary disease.” Wien Med Wochenschr 159, no. 23–24 (December 2009): 583–90. https://doi.org/10.1007/s10354-009-0727-z.
       Full Text  Link to Item
    • Abernethy, Amy P., Sally Y. Barbour, Hope Uronis, S Yousuf Zafar, April Coan, Krista Rowe, Mary Ruth Pupa, Jane L. Wheeler, and James E. Herndon. “Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.” Support Care Cancer 17, no. 6 (June 2009): 735–44. https://doi.org/10.1007/s00520-008-0562-6.
       Full Text  Link to Item
    • Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 4080.
       Link to Item
    • Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 3551.
       Link to Item
    • Uronis, H. E., K. Bullock, G. Blobe, S. Hsu, M. Morse, A. Nixon, S. Haley, M. O’Neill, H. Hurwitz, and J. Bendell. “A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e15506.
       Link to Item
    • Abernethy, A. P., H. E. Uronis, J. L. Wheeler, and D. C. Currow. “Pharmacological management of breathlessness in advanced disease.” Progress in Palliative Care 16, no. 1 (August 25, 2008): 15–20. https://doi.org/10.1179/096992608X291243.
       Full Text
    • Uronis, Hope E., and Amy P. Abernethy. “Oxygen for relief of dyspnea: what is the evidence?” Curr Opin Support Palliat Care 2, no. 2 (June 2008): 89–94. https://doi.org/10.1097/SPC.0b013e3282ff0f5d.
       Full Text  Link to Item
    • Bendell, J. C., H. E. Uronis, M. A. Morse, G. Blobe, M. Aklilu, A. Nixon, D. Niedzweicki, W. Honeycutt, L. Howard, and H. Hurwitz. “Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4063.
       Link to Item
    • Bendell, J. C., H. E. Uronis, M. A. Morse, G. Blobe, M. Aklilu, A. Nixon, D. Niedzweicki, W. Honeycutt, L. Howard, and H. Hurwitz. “Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4063–4063. https://doi.org/10.1200/jco.2008.26.15_suppl.4063.
       Full Text
    • Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 17528.
       Link to Item
    • Uronis, H. E., D. C. Currow, D. C. McCrory, G. P. Samsa, and A. P. Abernethy. “Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis.” Br J Cancer 98, no. 2 (January 29, 2008): 294–99. https://doi.org/10.1038/sj.bjc.6604161.
       Full Text  Open Access Copy  Link to Item
    • Uronis, H. E., D. C. McCrory, G. P. Samsa, D. C. Currow, and A. Abernethy. “Palliative oxygen for non-hypoxaemic chronic obstructive pulmonary disease.” Cochrane Database of Systematic Reviews, no. 2 (December 1, 2007). https://doi.org/10.1002/14651858.CD006429.
       Full Text
    • Uronis, Hope E., and Johanna C. Bendell. “Anal cancer: an overview.” Oncologist 12, no. 5 (May 2007): 524–34. https://doi.org/10.1634/theoncologist.12-5-524.
       Full Text  Link to Item
    • Uronis, Hope E., and Herbert I. Hurwitz. “Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?” Nat Clin Pract Oncol 4, no. 4 (April 2007): 214–15. https://doi.org/10.1038/ncponc0748.
       Full Text  Link to Item
    • Uronis, Hope E., David C. Currow, and Amy P. Abernethy. “Palliative management of refractory dyspnea in COPD.” Int J Chron Obstruct Pulmon Dis 1, no. 3 (2006): 289–304. https://doi.org/10.2147/copd.2006.1.3.289.
       Full Text  Link to Item

  • Conference Papers

    • Klempner, Samuel J., Joseph Chao, Hope Elizabeth Uronis, Cynthia A. Sirard, Michael Kagey, Jason Baum, James Song, et al. “DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.” In Journal of Clinical Oncology, 40:292–292. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.4_suppl.292.
       Full Text
    • Sharib, Jeremy, Annie Liu, John Creasy, Benjamin Wildman-Tobriner, Hope Elizabeth Uronis, John H. Strickler, David S. Hsu, Sabino Zani, Peter J. Allen, and Michael Lidsky. “Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.” In Journal of Clinical Oncology, 40:120–120. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.4_suppl.120.
       Full Text
    • Miller, Shannon N., Grace H. Amaden, Hannah M. Fisher, Joseph G. Winger, Tamara J. Somers, Hope E. Uronis, Luana Colloca, Francis Keefe, and Sarah A. Kelleher. “FEASIBILITY, ACCEPTABILITY, AND SAFETY OF A VIRTUAL REALITY PROTOCOL FOR PATIENTS WITH ADVANCED COLORECTAL CANCER.” In Annals of Behavioral Medicine, 56:S453–S453, 2022.
       Link to Item
    • Kelly, Ronan Joseph, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Mendez, et al. “Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.” In Journal of Clinical Oncology, 39:4003–4003. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4003.
       Full Text
    • Morse, Michael, Daniel M. Halperin, Hope Elizabeth Uronis, David S. Hsu, Herbert Hurwitz, Emily Bolch, Dana Warren, et al. “Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).” In Journal of Clinical Oncology, 39:369–369. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.369.
       Full Text
    • Uronis, Hope Elizabeth, Christel Rushing, Gerard C. Blobe, Shiaowen David Hsu, Niharika B. Mettu, James Leroy Wells, Donna Niedzwiecki, et al. “KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma.” In Journal of Clinical Oncology, 39:228–228. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.228.
       Full Text
    • Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.
       Full Text  Link to Item
    • Catenacci, Daniel V. T., Kian Huat Lim, Hope Elizabeth Uronis, Yoon-Koo Kang, Matthew C. H. Ng, Philip Jordan Gold, Peter C. Enzinger, et al. “Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).” In Journal of Clinical Oncology, 37:65–65. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.65.
       Full Text
    • Catenacci, D. V. T., H. Park, H. E. Uronis, Y. -. K. Kang, M. Ng, P. Gold, J. Lacy, et al. “Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA).” In Ann Oncol, 29 Suppl 8:viii223, 2018. https://doi.org/10.1093/annonc/mdy282.046.
       Full Text  Link to Item
    • Wang, J., S. V. Liu, H. E. Uronis, C. Wu, D. Mahalingam, A. Spira, L. Carter, et al. “Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial.” In Ann Oncol, 29 Suppl 8:viii404–5, 2018. https://doi.org/10.1093/annonc/mdy288.012.
       Full Text  Link to Item
    • Catenacci, Daniel V. T., Haeseong Park, Hope Elizabeth Uronis, Yoon-Koo Kang, Jill Lacy, Peter C. Enzinger, Se Hoon Park, et al. “Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).” In Journal of Clinical Oncology, 36:4030–4030. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4030.
       Full Text
    • Jia, Jingquan, Donna Niedzwiecki, Hope Elizabeth Uronis, Michael Morse, Yousuf Zafar, Shiaowen David Hsu, Emily Bolch, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.” In Journal of Clinical Oncology, 36:3555–3555. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3555.
       Full Text
    • Kelly, Karen, Melissa Lynne Johnson, Devalingam Mahalingam, Stephen V. Liu, Hope Elizabeth Uronis, Christina Wu, Laura Carter, et al. “A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.” In Journal of Clinical Oncology, 36:TPS2617–TPS2617. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps2617.
       Full Text
    • Palta, Manisha, Brian G. Czito, Eileen Duffy, Mary Malicki, Donna Niedzwiecki, James L. Abbruzzese, Hope Elizabeth Uronis, Gerard C. Blobe, Dan G. Blazer, and Christopher Willett. “A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.” In Journal of Clinical Oncology, 36:4121–4121. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4121.
       Full Text
    • Catenacci, Daniel V. T., Haeseong Park, A Craig Lockhart, Philip Jordan Gold, Peter C. Enzinger, Jeffrey L. Nordstrom, Sam Hong, et al. “Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
       Link to Item
    • Catenacci, Daniel V. T., Sunnie S. Kim, Philip Jordan Gold, Philip Agop Philip, Peter C. Enzinger, Joe Coffie, Emmett V. Schmidt, et al. “A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.” In Journal of Clinical Oncology, 35:TPS219–TPS219. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.4_suppl.tps219.
       Full Text
    • Porter, Laura S., Laura FIsh, Hope Elizabeth Uronis, Yousuf Zafar, and Karen E. Steinhauser. “The elephant in the room: Facilitating conversations about advanced cancer between patients and their spouses.” In Journal of Clinical Oncology, 34:233–233. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.26_suppl.233.
       Full Text
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).” In Journal of Clinical Oncology, 34:e15013–e15013. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e15013.
       Full Text
    • Morris, Van Karlyle, Kristen Keon Ciombor, Mohamed E. Salem, Halla Sayed Nimeiri, Syma Iqbal, Preet Paul Singh, Blase N. Polite, et al. “NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).” In Journal of Clinical Oncology, 34:3503–3503. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3503.
       Full Text
    • Strickler, John H., Christel N. Rushing, Hope Elizabeth Uronis, Michael Morse, Gerard C. Blobe, Yousuf Zafar, Shiaowen David Hsu, et al. “Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 34:3548–3548. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3548.
       Full Text
    • Strickler, John H., Fatima A. Rangwala, Christel Rushing, Donna Niedzwiecki, Ivy Altomare, Hope Elizabeth Uronis, Shiaowen David Hsu, et al. “X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 34:687–687. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.4_suppl.687.
       Full Text
    • Ryan, David P., Shantan G. Reddy, Nathan Bahary, Hope Elizabeth Uronis, Darren Sigal, Allen Lee Cohn, William R. Schelman, Joe Stephenson, Clarence Eng, and Mitesh J. Borad. “TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC).” In Journal of Clinical Oncology, 31:325–325. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.4_suppl.325.
       Full Text
    • Zhong, J., M. Palta, C. G. Willett, S. J. McCall, F. McSherry, H. E. Uronis, D. S. Tyler, and B. G. Czito. “Patterns of Failure for Stage I Ampulla of Vater Adenocarcinoma: A Single Institutional Experience.” In International Journal of Radiation Oncology Biology Physics, 87:S317–S317, 2013. https://doi.org/10.1016/j.ijrobp.2013.06.832.
       Full Text  Link to Item
    • Rangwala, Fatima A., Johanna C. Bendell, Mark Kozloff, Christy Arrowood, Jennifer Meadows, Sandra Ellen Tourt-Uhlig, Jennifer Murphy, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” In Journal of Clinical Oncology, 30:490–490. American Society of Clinical Oncology (ASCO), 2012. https://doi.org/10.1200/jco.2012.30.4_suppl.490.
       Full Text
    • Pepek, J. M., J. P. Chino, C. G. Willett, D. S. Tyler, H. E. Uronis, and B. G. Czito. “Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Adenocarcinoma: A Single Institution Experience.” In International Journal of Radiation Oncology*Biology*Physics, 78:S73–S73. Elsevier BV, 2010. https://doi.org/10.1016/j.ijrobp.2010.07.203.
       Full Text
    • Altomare, I., K. B. Russell, H. E. Uronis, M. Morse, S. D. Hsu, Y. Zafar, J. C. Bendell, A. Starodub, W. Honeycutt, and H. Hurwitz. “Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 28:3535–3535. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.3535.
       Full Text
    • Drouin, M. A., C. K. Kollmannsberger, H. E. Uronis, R. E. Martell, J. Wang, M. Dubay, I. Dupont, J. M. Besterman, H. Hurwitz, and G. Shapiro. “Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101).” In Journal of Clinical Oncology, 28:3106–3106. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.3106.
       Full Text
    • Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Lewis, N., R. B. Cohen, Y. Nishida, H. I. Hurwitz, C. Arrowwood, H. E. Uronis, F. Gamza, C. Longley, A. Buchbinder, and J. Figueroa. “398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours.” In European Journal of Cancer Supplements, 6:125–125. Elsevier BV, 2008. https://doi.org/10.1016/s1359-6349(08)72332-2.
       Full Text
    • Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” In Journal of Clinical Oncology, 26:17528–17528. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.17528.
       Full Text
    • Uronis, H. E., J. Bendell, G. Blobe, M. Morse, D. Geier, A. Nixon, L. Howard, D. Evans, H. Li, and H. Hurwitz. “A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.